| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Autogramin-1 targets the autophagy pathway, specifically inhibiting autophagosome formation and autophagy flux. The exact molecular target of autogramin-1 within the autophagy machinery is being elucidated, but the compound is known to block the early stages of autophagy, preventing the formation of autophagosomes.
|
|---|---|
| ln Vitro |
Autogramin-1 demonstrates potent in vitro inhibition of autophagy. It inhibits the formation of autophagosomes and blocks autophagy flux in cultured cells. The compound's activity is typically assessed by measuring the levels of autophagy markers such as LC3-II and p62 using Western blotting, or by using fluorescent autophagy reporters.
|
| ln Vivo |
In vivo activity of autogramin-1 has been suggested by its ability to inhibit autophagy in cell-based assays. The compound is used as a research tool to study the role of autophagy in various diseases. Further in vivo studies are needed to evaluate its efficacy in animal models of autophagy-related diseases.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for autogramin-1 are not extensively documented, as its exact molecular target is being elucidated. Its effects on autophagy are assessed by measuring autophagy markers such as LC3-II conversion and p62 degradation using Western blotting.
|
| Cell Assay |
In vitro cellular assays for autogramin-1 involve treating cells with varying concentrations of the compound and measuring autophagy markers. LC3-II levels are assessed by Western blotting or immunofluorescence. p62 levels are measured to assess autophagy flux. Autophagosome formation is visualized using fluorescent reporters or electron microscopy.
|
| Animal Protocol |
In vivo animal experiments for autogramin-1 are not extensively documented. If used in animal models, typical protocols would involve administering the compound to models of cancer, neurodegeneration, or infection and evaluating efficacy by measuring disease progression and autophagy markers in tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for autogramin-1 are limited. The compound has a molecular weight of 372.42 and a molecular formula of C22H20N4O2. It is soluble in DMSO at 50 mg/mL (134.26 mM). Powder should be stored at -20°C for up to 3 years; solutions at -80°C for up to 6 months. Its ADME properties have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for autogramin-1 are limited. As a research compound, comprehensive toxicological studies have not been reported. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Autogramin-1 (CAS#: 2375541-73-2) has the molecular formula C22H20N4O2 and a molecular weight of 372.42. It is a small molecule inhibitor of autophagy that inhibits autophagosome formation and blocks autophagy flux. The compound is used as a research tool to study the role of autophagy in cancer, neurodegeneration, and infection. It is for research use only.
|
| Molecular Formula |
C23H27N5O5S
|
|---|---|
| Molecular Weight |
485.56
|
| Exact Mass |
485.173
|
| CAS # |
2375541-73-2
|
| PubChem CID |
138106864
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.627
|
| LogP |
3.33
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
34
|
| Complexity |
833
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCN1C(=O)C2=C(C=C(C=C2)C(=O)NC3=NC4=C(S3)CN(CC4)C(=O)OC(C)(C)C)NC1=O
|
| InChi Key |
SKCCDKMWKFQCQC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H27N5O5S/c1-5-9-28-19(30)14-7-6-13(11-16(14)25-21(28)31)18(29)26-20-24-15-8-10-27(12-17(15)34-20)22(32)33-23(2,3)4/h6-7,11H,5,8-10,12H2,1-4H3,(H,25,31)(H,24,26,29)
|
| Chemical Name |
tert-butyl 2-[(2,4-dioxo-3-propyl-1H-quinazoline-7-carbonyl)amino]-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 6.94 mg/mL (14.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0595 mL | 10.2974 mL | 20.5948 mL | |
| 5 mM | 0.4119 mL | 2.0595 mL | 4.1190 mL | |
| 10 mM | 0.2059 mL | 1.0297 mL | 2.0595 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
